Intrahepatic Cholangiocarcinoma.

Area of Science:

• Hepatobiliary cancers
• Gastroenterology
• Surgical oncology

Background:

• Cholangiocarcinoma is a rare biliary tract cancer with poor prognosis.
• Limited therapeutic options and challenging histology contribute to poor outcomes.
• Recent advances in locoregional therapy show promise for managing this malignancy.

Purpose of the Study:

• To review recent advances in locoregional therapy for cholangiocarcinoma.
• To highlight the role of portal vein embolization in improving surgical eligibility.
• To discuss the efficacy of transarterial chemoembolization and yttrium-90 radioembolization for unresectable disease.

Main Methods:

• Review of current literature on locoregional therapies for cholangiocarcinoma.
• Analysis of the impact of portal vein embolization on surgical candidacy.
• Evaluation of outcomes for transarterial chemoembolization and yttrium-90 radioembolization.

Main Results:

• Portal vein embolization can induce liver hypertrophy, increasing resectability.
• Transarterial chemoembolization and yttrium-90 radioembolization demonstrate effectiveness in tumor growth control.
• These locoregional therapies can prolong survival in patients with unresectable cholangiocarcinoma.

Conclusions:

• Locoregional therapies represent a significant advancement in managing cholangiocarcinoma.
• Portal vein embolization expands surgical options for patients with adequate hepatic reserve.
• Transarterial chemoembolization and yttrium-90 radioembolization offer valuable treatment strategies for unresectable cholangiocarcinoma.